Dermatology Times

11/06/2025

👥 🤠 CONFERENCE PREVIEW: We are here at the Meeting in San Antonio! Will you be attending? Let us know and check out our full conference preview below ⬇️

Preview the SDPA Fall 2025 conference in San Antonio for 4 days of networking, education, and expert-led sessions for dermatology PAs.

11/05/2025

🚨NEW: The FDA has issued 18 warning letters to the operators of websites illegally marketing unapproved and misbranded botulinum toxin products.

The FDA emphasized that these unapproved formulations pose serious health risks, including botulism symptoms, and have already been linked to adverse events.

Read more about the websites:

The FDA issued 18 warning letters to websites illegally selling unapproved and misbranded botulinum toxin products, citing serious safety risks including botulism-related adverse events.

11/05/2025

☎️▶️ DERM DISPATCH: advocate Chava Wald shares her lifelong journey with atopic dermatitis with Renata Block, DMSc, MMS, PA-C.

Her story highlights resilience, empathy, and how compassionate care transforms outcomes for patients and clinicians alike.

🎥 Watch the full interview now: https://hubs.li/Q03RHH6V0

Chava Wald shares her inspiring journey with AD, advocating for patient empowerment and compassionate care during Eczema Awareness Month.

11/05/2025

💡 EXPERT INSIGHTS: Andrew Mastro, PA-C, and Aaron Sookhoo, PA-C, share their vision for a unified national NP/PA network—“50 states, 50 societies.” In this exclusive interview with Dermatology Times, they reminded those in the space that leadership grows through collaboration, passion, and inclusion.

🎥 Watch the full interview now:

Aaron Sookhoo, PA-C, and Andrew Mastro, PA-C, outline their long-term vision for the National Dermatology Leadership Summit, promoting collaboration and advocacy.

11/04/2025

💡 EXPERT INSIGHTS: At , Shawn Kwatra, MD, discussed what he is looking forward to in 2026, including icotrokinra for psoriasis, nemolizumab for chronic pruritus of unknown origin, and povorcitinib for prurigo nodularis.

🎥 Watch the full interview now: https://hubs.li/Q03RsYz50

11/03/2025

🩷 Breast Cancer Awareness Month may be over but the collaboration between dermatologists and oncologists must continue. Learn more from our Editor in Chief, Christopher Bunick, MD, PhD, and read our special edition October supplement to stay up the date on the latest resources and guidance for these patients ⬇️

https://hubs.ly/Q03RnTMC0

11/03/2025

💡 EXPERT INSIGHTS: The first National Dermatology Leadership Summit launches in 2026 to unite PAs and NPs nationwide, advancing education, advocacy, and collaboration to strengthen dermatology’s APP community.

Aaron Sookhoo, PA-C, and Andrew Mastro, PA-C, met with Dermatology Times to discuss their vision for the inaugural NDLS.

🎥 Watch the full interview now:

Discover how the National Dermatology Leadership Summit will unite PAs and NPs to enhance collaboration, education, and advocacy in dermatology.

11/01/2025

🌟 As Eczema Awareness Month comes to a close, Dermatology Times has compiled the top news insights and expert-led interviews from the month that are shaping the future of diagnosis, research, and treatment for patients with atopic dermatitis ⬇️

https://hubs.li/Q03R8Zch0

Discover the latest advancements in atopic dermatitis treatment and patient advocacy during Eczema Awareness Month, shaping future care and quality of life.

11/01/2025

🎥 Is APG777 the next major player in atopic dermatitis care? Explore compelling phase 2 trial efficacy data presented at EADV and see what has clinicians talking.

Dive into the evidence: https://hubs.li/Q03R9BR90

10/31/2025

Don’t miss what you might’ve missed! September’s cover story explored how Mohs surgeons balance cure and cosmesis, especially in complex areas like the eyelids, lips, and nails.

Subscribe for monthly insights delivered to your inbox: https://hubs.li/Q03R9FPt0

10/31/2025

💡 EXPERT INSIGHTS: At Fall Clinical 2025, Ron Vender, MD, discussed how new oral TYK2 inhibitors may be taking over the previously injectable-dominant space in .

🎥 Watch the full interview now: https://hubs.li/Q03R8jHT0

10/31/2025

👥 CONFERENCE HIGHLIGHTS: At , Lisa Swanson, MD, discussed oral IL-23 inhibition in pediatric care. shows durable PASI responses with favorable safety, while guselkumab’s trial delivers superior pediatric efficacy.

🎥 Watch the full interview now: https://hubs.li/Q03R1zGH0

At Fall Clinical 2025, experts discussed the science behind oral IL-23 inhibition, potentially ending the injection-only era for psoriasis therapy.